» Articles » PMID: 37302808

WDR54 Exerts Oncogenic Roles in T-cell Acute Lymphoblastic Leukemia

Overview
Journal Cancer Sci
Specialty Oncology
Date 2023 Jun 11
PMID 37302808
Authors
Affiliations
Soon will be listed here.
Abstract

WDR54 has been recently identified as a novel oncogene in colorectal and bladder cancers. However, the expression and function of WDR54 in T-cell acute lymphoblastic leukemia (T-ALL) were not reported. In this study, we investigated the expression of WDR54 in T-ALL, as well as its function in T-ALL pathogenesis using cell lines and T-ALL xenograft. Bioinformatics analysis indicated high mRNA expression of WDR54 in T-ALL. We further confirmed that the expression of WDR54 was significantly elevated in T-ALL. Depletion of WDR54 dramatically inhibited cell viability and induced apoptosis and cell cycle arrest at S phase in T-ALL cells in vitro. Moreover, knockdown of WDR54 impeded the process of leukemogenesis in a Jurkat xenograft model in vivo. Mechanistically, the expression of PDPK1, phospho-AKT (p-AKT), total AKT, phospho-ERK (p-ERK), Bcl-2 and Bcl-xL were downregulated, while cleaved caspase-3 and cleaved caspase-9 were upregulated in T-ALL cells with WDR54 knockdown. Additionally, RNA-seq analysis indicated that WDR54 might regulate the expression of some oncogenic genes involved in multiple signaling pathways. Taken together, these findings suggest that WDR54 may be involved in the pathogenesis of T-ALL and serve as a potential therapeutic target for the treatment of T-ALL.

Citing Articles

Identification of novel therapeutic targets for head and neck squamous cell carcinoma through bioinformatics analysis.

Jeong E, Kim E, Kim Y Sci Rep. 2024; 14(1):32102.

PMID: 39739088 PMC: 11686289. DOI: 10.1038/s41598-024-83680-1.


WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia.

Li H, Zhang D, Fu Q, Wang S, Zhang X, Lin Z Cancer Sci. 2023; 114(8):3318-3329.

PMID: 37302808 PMC: 10394158. DOI: 10.1111/cas.15872.

References
1.
Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R . Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015; 11(8):571-578. PMC: 4511833. DOI: 10.1038/nchembio.1859. View

2.
Schapira M, Tyers M, Torrent M, Arrowsmith C . WD40 repeat domain proteins: a novel target class?. Nat Rev Drug Discov. 2017; 16(11):773-786. PMC: 5975957. DOI: 10.1038/nrd.2017.179. View

3.
Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Bene M . Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010; 28(15):2529-37. PMC: 5569671. DOI: 10.1200/JCO.2009.23.4732. View

4.
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson M . The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49(8):1211-1218. PMC: 5535770. DOI: 10.1038/ng.3909. View

5.
Stirnimann C, Petsalaki E, Russell R, Muller C . WD40 proteins propel cellular networks. Trends Biochem Sci. 2010; 35(10):565-74. DOI: 10.1016/j.tibs.2010.04.003. View